Richmond, B.C. named Canada's Most Active Community Français
TORONTO, July 22, 2025 /CNW/ - Richmond, B.C. has been named Canada's Most Active Community and awarded the $100,000 grand prize to support local physical activity and sport initiatives as part of the ParticipACTION Community Challenge presented by Novo Nordisk. Now in its sixth year, the national physical activity and sport initiative encourages Canadians to get active throughout the month of June.
"Congratulations to Richmond and all of the provincial and territorial winners," said Elio Antunes, President and CEO of ParticipACTION. "Engaging community members in physical activity and sport is an important strategy for building healthier and more connected communities. It was so inspiring to see over 1,500 organizations host more than 10,000 low-barrier, inclusive physical activity and sport activities throughout June. We hope communities keep the momentum going and continue to make room to move year-round!"
Richmond has been a strong competitor in the Community Challenge since its inception and won the title of B.C.'s Most Active Community in 2022 and 2024. This year, the city earned the title of Canada's Most Active Community with the help of local organizations that rallied people to get active through more than 1,000 programs and activities. Many of them were free or low cost, helping reduce barriers and supporting Richmond's commitment to building an inclusive and accessible community.
"The City of Richmond is proud of our commitment to support physical activity and well-being," said Malcolm Brodie, Mayor of Richmond, B.C. "As a vibrant and active community, we provide safe, fun and inclusive opportunities for all ages to keep our people connected and promote healthy lifestyles. On behalf of the many organizations and individuals that support physical activity and well-being in Richmond, we are honoured to be named Canada's Most Active Community."
Since the Community Challenge began in 2019, ParticipACTION has awarded $1.5 million to winning communities to support local physical activity and sport initiatives. To help level the playing field and facilitate accessible opportunities for people in Canada to get active during the Challenge, ParticipACTION has also awarded over $7 million in grants to organizations across the country to provide physical activity and sport opportunities for equity-denied groups.
"Congratulations to all of the communities that took part in the ParticipACTION Community Challenge, and to this year's Most Active Community. It is inspiring to see Canadians come together to create stronger, healthier, and more active communities across the country – creating momentum for active lifestyles in Canada." — The Honourable Marjorie Michel, Minister of Health
ParticipACTION also awarded between $7,500 and $15,000 to the following communities from each province and territory to recognize their outstanding efforts to engage their residents in physical activity and sport:
Red Deer, AB
Pinawa, MB
Grand-Bouctouche, NB
Clarenville, NL
Truro and Cape Breton, NS (tie)
Hay River, NT
Iqaluit, NU
Cochrane, ON
Miltonvale Park, PE
Québec City, QC
Ituna, SK
Faro, YT
"By making sport more inclusive and accessible for everyone, our government is building stronger, healthier communities," said the Honourable Adam van Koeverden, Secretary of State (Sport). "The ParticipACTION Community Challenge is a fantastic program that we are proud to support. Way to go, Richmond, B.C.! Congratulations and thank you for inspiring your neighbours and all Canadians to keep moving!"
The 2025 Community Challenge took place from June 1 to 30 and was open to all communities, organizations and individuals across Canada. Over 846,000 participants and 672 communities participated in the Challenge and competed for the title of Canada's Most Active Community.
"On behalf of Novo Nordisk Canada, congratulations to Richmond and to all the provincial and territorial winners, along with every individual who took part in this year's ParticipACTION Community Challenge. Novo Nordisk is proud to be the presenting partner of this important initiative, which plays a vital role in supporting a healthier Canada through the promotion of physical activity and prevention of chronic diseases." — Vince Lamanna, President of Novo Nordisk Canada
Everyone in Canada should have access to quality sport and physical activity opportunities that help them grow and thrive—physically, emotionally and socially. From drag queen-led fitness events to sunrise hikes for newcomers and sensory-friendly swimming programs, communities across Canada made room to move during the Community Challenge, helping create a healthier, stronger country.
About ParticipACTION
ParticipACTION is a national non-profit charitable organization that envisions a Canada where physical activity is a vital part of everyday life for everyone. As Canada's leading physical activity organization, ParticipACTION works with its partners, which include organizations in the sport, physical activity and recreation sectors, alongside government and corporate sponsors, to help people move more where they live, learn, work and play. ParticipACTION is generously supported by the Government of Canada. Learn how ParticipACTION has been moving Canadians for over 50 years at ParticipACTION.com.
About the Community Challenge
The ParticipACTION Community Challenge presented by Novo Nordisk is a national physical activity and sport initiative that encourages everyone in Canada to get active throughout June in search of Canada's Most Active Community. The Community Challenge is open to all communities and individuals, ultimately recognizing Canada's Most Active Community and awarding it $100,000 to support local physical activity and sport initiatives. The ParticipACTION Community Challenge presented by Novo Nordisk is proudly funded by the Government of Canada and Novo Nordisk.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
36 minutes ago
- Cision Canada
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /CNW/ -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform is poised to redefine the landscape of biomarker detection, offering unprecedented sensitivity, specificity and multiplex detection for neurodegenerative disease diagnosis and monitoring. This year's AAIC marks the first public presentation of robust clinical data generated using NULISA to measure brain-derived pTaus alongside over 120 key CNS disease-related proteins, an achievement that could accelerate both early detection and therapeutic monitoring in Alzheimer's and related neurodegenerative conditions. "The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for neurodegenerative diseases," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. These data will be presented during Alamar's product theater on Monday, July 28, 1:20 PM ET, featuring Prof. Jonathan Schott from University College London and the UK DRI, and Dr. Cheryl Wellington from the University of British Columbia. Highlights include: Brain-Derived pTau Performance: The presentation will showcase data from the 1946 Birth Cohort featuring the new brain-derived pTau isoforms using the NULISAseq™ CNS Disease Panel 120 in both presymptomatic and post-AD diagnosis samples, highlighting the superior ability of brain-derived pTaus to predict Alzheimer's disease years before it was diagnosed Correlations with Disease Progression: Data will demonstrate the correlation between brain-derived pTau levels and amyloid and Tau PET imaging Biomarkers for neuropathologies and AD co-pathologies: Analysis of a unique cohort of patients with autopsy-confirmed pathologies with the NULISAseq™ CNS Disease Panel 120 identified biomarkers for detecting neuropathologies and AD co-pathologies. Preclinical research: The NULISAseq™ Mouse Panel 120 demonstrated utility in analysis of plasma and brain homogenate samples from multiple clinical models of AD. The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the scientific community focused on dementia and Alzheimer's research. Every year, the conference gathers leading experts, scientists, clinicians, and stakeholders to share the latest discoveries, foster collaborations, and accelerate the quest for effective diagnostics and therapies. See here for a full list of posters and presentations featuring NULISA data during the AAIC meeting. About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
CTV News
an hour ago
- CTV News
The importance of early detection and prevention of skin cancer
With summer in full gear, Merck is launching its annual Skintimacy campaign to educate Canadians about the importance of sun protection, early detection, and prevention of skin cancer. Dr. Jason Rivers tells us more.
Cision Canada
an hour ago
- Cision Canada
Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference
Analysis of first-in-class CNS-101 study validates that at-home endpoints showed greater separation with Alzheimer's pathology (pTau217) than the benchmark endpoint Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 13) over the study time-course BELFAST, Northern Ireland, July 28, 2025 /CNW/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data from their real-world observational study CNS-101 at the Alzheimer's Association International Conference 2025 in Toronto, Ontario, Canada. Using the proprietary NeuLogiq ® Platform to gather data via repeated at-home sampling, the study was conducted in collaboration with the University of Cambridge. Cumulus presented a poster titled, "Frequent at-home multimodal measurements are more sensitive to progression than the gold-standard clinic-based ADAS-Cog composite scale" which featured data confirming repeated home-based digital cognitive endpoints are more sensitive to disease progression than the ADAS-Cog 13 composite benchmark, the primary cognitive scale used in Alzheimer's clinical trials today to determine drug efficacy. Additionally, passive electroencephalography (EEG) markers and naturalistic language-based markers collected with the NeuLogiq Platform are similarly powerful at detecting dementia progression as the ADAS-Cog 13, which requires a trained clinician and takes ~45 minutes to administer. "Clinic-based endpoints reflect snapshots in time, which limits the ability to track true disease progression and therapeutic efficacy in clinical research. Additionally, these endpoints lack sensitivity, objectivity, and are not scalable," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Our CNS-101 study was executed in collaboration with the Cumulus Pharma Advisory Group, which is comprised of leading scientists from ten top pharma companies. This first-in-class study has validated that patients living with Alzheimer's dementia are capable and willing to participate in clinical studies that include at-home longitudinal measures. Our NeuLogiq platform, which includes an award-winning FDA-cleared EEG headset, is user-friendly and suitable for repeated at-home use. We now have evidence that repeated real-world measurements at home provide higher statistical power than ADAS-Cog and could enable leaner study designs. We are deeply grateful to all the study participants and research collaborators." Additional analysis demonstrated that individual digital endpoints can enable streamlined study designs which may reduce overall costs, accelerating results leading to earlier go/no go decisions. In collaboration with the Cumulus Pharma Advisory Group, Cumulus will validate whether a digital composite measure may provide additional study power. "It's promising to see the increased sensitivity and statistical power of digital biomarkers from the wealth of data collected both at home and in the clinic in CNS-101," said Dr. Emer MacSweeney, Co-Founder & CEO of Re:Cognition Health's Brain and Mind Clinics which served as a leading CNS-101 clinical site. "The burden on study participants and patients is an important consideration when designing a clinical study in Alzheimer's Disease. Studies like CNS-101 are important to show the validity and sensitivity of digital biomarkers in developing CNS therapies and reducing the impact on patients and clinicians alike." Alzheimer's is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, difficulty with language and communication, mood swings, and changes in behavior and personality. While there is no known cure, there are currently over one hundred Alzheimer's disease clinical trials underway. In the CNS-101 Study, patients with dementia (N=59, ACE-III scores >60 and ≤88) and a matched cohort of healthy controls (N=60) were recruited across 7 sites in the UK including Cambridge and Oxford Universities and Re:Cognition Health's Brain and Mind Clinics in Plymouth and Guildford, for a 12-month repeated sampling study. Plasma samples were collected to confirm disease pathology. Participants were asked to complete repeated home-based sessions using the platform during the day, and to wear a sleep EEG device at night. Day sessions with a duration of approximately 30 minutes included 8 behavioral assessments on a mobile tablet (memory, executive function, affective processing and language) while synchronized EEG was recorded using the Cumulus 16-lead EEG headset. A staggered longitudinal protocol followed with burst sampling tapering to periodic sampling over the year. Benchmark paper-based assessments (including ADAS-Cog) and self-reported usability were collected at months 0, 6, and 12. Blood plasma was collected at months 6 and 12 for later biomarker analysis. Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit About Cumulus Neuroscience With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing NeuLogiq ®, an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world's leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer's Disease, depression and schizophrenia. Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient's home – all with an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world's largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.
